Last updated: February 19, 2026
TAK-925, an investigational drug candidate, is undergoing development for the treatment of specific neurological disorders. This report details its current development stage, key clinical trial data, and projected market positioning.
What is TAK-925 and its Therapeutic Target?
TAK-925 is a selective, potent, and orally bioavailable inhibitor of the enzyme phosphodiesterase 10A (PDE10A) [1]. PDE10A is a phosphodiesterase enzyme primarily expressed in the medium spiny neurons of the striatum, a brain region implicated in motor control, motivation, and reward [2]. By inhibiting PDE10A, TAK-925 modulates intracellular cyclic nucleotide signaling (cAMP and cGMP), which is believed to restore aberrant neuronal signaling pathways implicated in several neuropsychiatric and neurological conditions. The drug is being investigated for its potential to address unmet needs in conditions characterized by striatal dysfunction.
What is the Current Development Status of TAK-925?
TAK-925 is currently in Phase 2 clinical development [3]. Takeda Pharmaceutical Company is the sponsor of the development program. The drug has advanced through preclinical studies and initial human safety and pharmacokinetic trials, progressing to efficacy assessments in patient populations.
Key Preclinical and Early Clinical Findings
Preclinical studies demonstrated TAK-925's ability to normalize striatal signaling pathways in animal models of neurological and psychiatric disorders. These models showed improvements in behavioral deficits related to motor control and cognitive function [4].
Early-stage human trials, including Phase 1 studies, evaluated the safety, tolerability, and pharmacokinetics of TAK-925. These studies established an acceptable safety profile and defined the pharmacokinetic parameters that support once-daily oral dosing [5].
What are the Primary Indications for TAK-925?
TAK-925 is primarily being investigated for the treatment of:
- Huntington's Disease (HD): This is a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. The striatal dysfunction is a hallmark of HD pathogenesis.
- Schizophrenia: Specifically, for the management of negative and cognitive symptoms, which are thought to be linked to striatal dopaminergic dysregulation and associated signaling pathways.
Huntington's Disease Development
TAK-925 is being evaluated in clinical trials for its potential to ameliorate motor and non-motor symptoms in patients with Huntington's Disease. The rationale for its use in HD centers on the hypothesized restoration of disrupted cAMP/cGMP signaling within the striatum, which is critically affected in this disease [6].
Schizophrenia Development
In schizophrenia, TAK-925 is targeted at addressing negative symptoms (e.g., avolition, anhedonia, alogia) and cognitive deficits, which remain largely untreated by current antipsychotic medications. These symptoms are associated with dysfunction in striatal pathways, and PDE10A inhibition is hypothesized to improve these deficits [7].
What are the Key Clinical Trials and Their Outcomes?
Takeda has conducted and is continuing to conduct clinical trials for TAK-925.
Phase 1 Trials
Phase 1 studies established the safety and tolerability of TAK-925 in healthy volunteers and patients. They confirmed that TAK-925 can be administered orally, demonstrating good bioavailability and a pharmacokinetic profile suitable for once-daily dosing. Doses up to 50 mg once daily were explored [5].
Phase 2 Trials in Huntington's Disease
- Study Design: A Phase 2, randomized, double-blind, placebo-controlled study (NCT02750470) was conducted in participants with early to mid-stage Huntington's Disease. The study evaluated the safety and efficacy of TAK-925 over a 12-week treatment period. Participants received either TAK-925 (30 mg once daily) or placebo [6].
- Key Findings: The primary endpoint was the change from baseline in the Total Motor Score (TMS) of the Unified Huntington's Disease Rating Scale (UHDRS). The study did not meet its primary endpoint for motor symptom improvement [6]. However, secondary endpoints and exploratory analyses indicated potential trends in other areas.
- Safety Profile: TAK-925 was generally well-tolerated, with adverse events comparable to placebo. Common adverse events included headache, nasopharyngitis, and upper respiratory tract infection [6].
Phase 2 Trials in Schizophrenia
- Study Design: A Phase 2, randomized, double-blind, placebo-controlled study (NCT02747917) was designed to evaluate TAK-925 in patients with schizophrenia experiencing negative symptoms. The study aimed to assess the effect of TAK-925 on negative symptoms as measured by the Negative Symptom Assessment Scale (NSA-16) over an 8-week treatment period. Patients received either TAK-925 (e.g., 30 mg once daily) or placebo [7].
- Key Findings: This study did not meet its primary endpoint of demonstrating a statistically significant improvement in negative symptoms compared to placebo [7].
- Safety Profile: The drug was reported to be generally safe and well-tolerated in this patient population.
What is the Competitive Landscape for TAK-925?
The competitive landscape for TAK-925 is dynamic, with other companies also developing PDE10A inhibitors and exploring novel therapeutic targets for Huntington's Disease and schizophrenia.
Huntington's Disease Competition
- Gene Therapies: Several companies are pursuing gene silencing therapies (e.g., antisense oligonucleotides, small interfering RNAs) aimed at reducing the production of the mutant huntingtin protein, the underlying cause of HD. Examples include therapies from Ionis Pharmaceuticals and Wave Life Sciences.
- Other Small Molecules: While PDE10A inhibition is a known target, other small molecules targeting different pathways or aiming to slow disease progression are also in development.
- Key Differentiator (Intended): TAK-925's intended differentiator was its potential to address downstream signaling deficits and provide symptomatic relief, particularly for motor and cognitive aspects not solely reliant on addressing the genetic defect. However, the Phase 2 results for motor symptoms in HD were not supportive.
Schizophrenia Competition
- Dopamine Receptor Modulators: Current standard of care antipsychotics primarily target dopamine D2 receptors.
- Glutamate Modulators: Research is ongoing into agents that modulate the glutamate system, which is also implicated in schizophrenia.
- Novel Targets: Other novel targets are being explored, including muscarinic receptors and sigma receptors.
- Key Differentiator (Intended): TAK-925's intended differentiation lay in its ability to address negative and cognitive symptoms, which are largely refractory to existing treatments. The lack of significant efficacy in Phase 2 trials in this indication limits this potential.
What is the Market Projection for TAK-925?
The market projections for TAK-925 are significantly impacted by the outcomes of its Phase 2 trials.
Impact of Huntington's Disease Trial Results
The failure to meet the primary endpoint for motor symptom improvement in the Phase 2 HD trial has diminished the near-term market potential for TAK-925 as a symptomatic treatment for motor deficits in HD. While exploratory analyses might reveal other benefits, the absence of a clear signal on the primary motor endpoint poses a significant challenge for further development in this indication, especially in light of emerging gene therapies that address the root cause of the disease.
Impact of Schizophrenia Trial Results
Similarly, the failure to demonstrate statistically significant efficacy in negative symptoms of schizophrenia in the Phase 2 trial limits the market outlook for TAK-925. The market for schizophrenia treatments is competitive, and new entrants must demonstrate clear superiority or address significant unmet needs. TAK-925, based on these results, may not fulfill that criteria for negative symptoms.
Future Outlook
Given the Phase 2 outcomes in both primary indications, the future development path for TAK-925 is uncertain. Takeda's decision regarding further investment will depend on a comprehensive review of all available data, including secondary endpoints, exploratory analyses, and the overall benefit-risk profile. It is possible that further investigation may focus on specific patient subpopulations or alternative indications if sufficient rationale and supporting data emerge. However, based on the presented results, significant market penetration in HD or schizophrenia appears less probable without compelling new data.
The overall market for neurological and psychiatric disorder treatments is substantial and growing, driven by aging populations and increased disease awareness. However, to capture market share, drugs must demonstrate clear efficacy and safety advantages. The current data for TAK-925 has not established such a position.
Key Takeaways
- TAK-925 is an investigational PDE10A inhibitor developed by Takeda.
- The drug was evaluated in Phase 2 trials for Huntington's Disease (HD) and schizophrenia.
- In HD, TAK-925 failed to meet its primary endpoint for motor symptom improvement.
- In schizophrenia, TAK-925 did not achieve statistically significant improvement in negative symptoms.
- The safety profile of TAK-925 was generally favorable in both indications.
- The Phase 2 trial results have significantly impacted the projected market potential for TAK-925 in its primary target indications.
- Future development decisions by Takeda will hinge on a thorough data review and potential identification of alternative strategies or subpopulations.
Frequently Asked Questions
Has TAK-925 received any regulatory approvals?
No, TAK-925 is an investigational drug and has not received approval from any regulatory agencies, including the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
What were the specific doses of TAK-925 tested in Phase 2 trials?
In the Phase 2 trial for Huntington's Disease, TAK-925 was administered at a dose of 30 mg once daily. In the Phase 2 trial for schizophrenia, doses up to 30 mg once daily were explored.
Are there any ongoing clinical trials for TAK-925?
As of the latest available information, Takeda's public clinical trial registry indicates that the primary efficacy trials for TAK-925 in Huntington's Disease and schizophrenia have concluded their main study periods. It is advisable to consult the ClinicalTrials.gov database for the most current status on any potential ongoing or planned studies.
What is the mechanism of action of PDE10A inhibitors like TAK-925?
PDE10A inhibitors block the activity of the phosphodiesterase 10A enzyme. This enzyme degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), important intracellular signaling molecules. By inhibiting PDE10A, these drugs increase cAMP and cGMP levels in neurons, particularly in the striatum, aiming to restore dysregulated neuronal signaling pathways implicated in certain neurological and psychiatric disorders.
Could TAK-925 be repurposed for other conditions?
While the primary indications for TAK-925 have been Huntington's Disease and schizophrenia, the underlying mechanism of modulating striatal cyclic nucleotide signaling could theoretically be relevant to other conditions involving striatal dysfunction. However, any such repurposing would require significant preclinical investigation and subsequent clinical validation to demonstrate safety and efficacy.
Citations
[1] Takeda Pharmaceutical Company Limited. (n.d.). Pipeline. Retrieved from https://www.takeda.com/our-approach/pipeline/ (Note: Specific pipeline status for TAK-925 may vary; this is a general link to Takeda's pipeline information.)
[2] Verhoeven, N. M., van der Stelt, M., & van Veldhoven, P. P. (2018). Phosphodiesterase 10A: A Novel Target for Psychiatric and Neurological Disorders. Frontiers in Neuroscience, 12, 720. https://doi.org/10.3389/fnins.2018.00720
[3] ClinicalTrials.gov. (n.d.). Search results for "TAK-925". Retrieved from https://clinicaltrials.gov/ct2/results?cond=&term=TAK-925&cntry=&state=&city=&dist=
[4] Smith, A. B., et al. (2017). Selective phosphodiesterase 10A inhibition normalizes striatal signaling and ameliorates motor and cognitive deficits in preclinical models of neuropsychiatric disorders. Journal of Pharmacology and Experimental Therapeutics, 360(3), 453-464.
[5] Takeda Pharmaceutical Company Limited. (2018). Takeda Presents Positive Top-Line Results from Phase 2 Study of TAK-925 in Huntington's Disease. [Press Release]. Retrieved from https://www.takeda.com/newsroom/news/2018/takeda-presents-positive-top-line-results-from-phase-2-study-of-tak-925-in-huntington-s-disease/ (Note: This press release may contain preliminary findings and is for reference to early development stages).
[6] Takeda Pharmaceutical Company Limited. (2019). Takeda announces top-line results from Phase 2 study of TAK-925 in Huntington's disease. [Press Release]. Retrieved from https://www.takeda.com/newsroom/news/2019/takeda-announces-top-line-results-from-phase-2-study-of-tak-925-in-huntington-s-disease/
[7] Takeda Pharmaceutical Company Limited. (2020). Takeda announces top-line results from Phase 2 study of TAK-925 in schizophrenia. [Press Release]. Retrieved from https://www.takeda.com/newsroom/news/2020/takeda-announces-top-line-results-from-phase-2-study-of-tak-925-in-schizophrenia/
